ライフサイエンスコーパス: levonorgestrel

1 efficacy of ulipristal acetate compared with levonorgestrel.

2 ver study comparing effects of OCPs (0.15 mg levonorgestrel + 0.30 ug ethinyl estradiol) vs placebo (

3 regimen (ethinyl estradiol, 100 microg, and levonorgestrel, 0.5 mg, repeated in 12 hours).

4 The levonorgestrel-only regimen (levonorgestrel, 0.75 mg, repeated in 12 hours) appears t

5 rone, 2.2 (1.5 to 3.2) and 2.3 (1.3 to 3.9); levonorgestrel, 1.7 (1.4 to 2.0) and 2.0 (1.6 to 2.5); n

6 l acetate, 213 events [19.3%] in 1104 women; levonorgestrel, 211 events [18.9%] in 1117 women).

7 ned participants in a 1:1 ratio to receive a levonorgestrel 52-mg IUD or a copper T380A IUD.

8 ts application for the continuous release of levonorgestrel-a contraceptive hormone.

9 ring device offering simultaneous release of levonorgestrel and dapivirine - a lead candidate antiret

10 second-generation progestogens (principally levonorgestrel and norethindrone) continues.

11 ssive motility, medroxyprogesterone acetate, levonorgestrel, and aldosterone had little effect on the

12 discovered that medroxyprogesterone acetate, levonorgestrel, and aldosterone inhibited calcium influx

13 The steroids medroxyprogesterone acetate, levonorgestrel, and aldosterone selectively antagonize p

14 ontributors to corticosteroid activities and levonorgestrel as the main contributor to progestogenic

15 Understanding and overcoming this levonorgestrel binding phenomenon is critical for the on

16 to be key parameters impacting the extent of levonorgestrel binding, each through their influence on

17 megestrol, algestone, norprogesterones, and levonorgestrel combined with terms such as systematic re

18 Secondary endpoints included week 48 levonorgestrel concentrations and unintended pregnancies

19 Week 24 geometric mean levonorgestrel concentrations were 528, 280, and 710 pg/

20 Week 48 levonorgestrel concentrations were 580, 247, and 664 pg/

21 The primary endpoint was week 24 levonorgestrel concentrations, compared between the ART-

22 pper intrauterine device (cu-IUD, n = 13) or levonorgestrel-containing combined oral contraceptives (

23 Post-release analysis included assessment of levonorgestrel distribution, particle size, porosity, an

24 Weekly sales of levonorgestrel emergency contraception per 1000 women of

25 Sales of levonorgestrel emergency contraception significantly inc

26 al in 29 UK pharmacies among women receiving levonorgestrel emergency contraception.

27 e not significantly associated with sales of levonorgestrel emergency contraception.

28 f evidence suggesting a relationship between levonorgestrel exposure and risk of depression.

29 evirapine-based ART did not adversely affect levonorgestrel exposure or efficacy.

30 Within 1 year of combined use, levonorgestrel exposure was markedly reduced in particip

31 ficacy and safety of ulipristal acetate with levonorgestrel for emergency contraception.

32 to slowly release the contraceptive hormone levonorgestrel for up to 1 month.

33 ic OCP (0.03 mg ethinylestradiol and 0.15 mg levonorgestrel) for contraception for at least 1 year we

34 thinylestradiol, bifenthrin, trenbolone, and levonorgestrel from 8 hpf to 21 dph.

35 e group (1.8%, 95% CI 1.0-3.0) and 22 in the levonorgestrel group (2.6%, 1.7-3.9; odds ratio [OR] 0.6

36 ate group and 35 (2.2%) in 1625 women in the levonorgestrel group (OR 0.58, 0.33-0.99; p=0.046).

37 onfidence interval [CI], 0.01 to 1.7) in the levonorgestrel group and 0 in 321 (0%; 95% CI, 0 to 1.1)

38 Of these, 290 in the levonorgestrel group and 300 in the copper IUD group had

39 three pregnancies, all of which were in the levonorgestrel group.

40 l acetate group and a molar pregnancy in the levonorgestrel group.

41 The contraceptive implant Norplant (levonorgestrel) had a fairly short life in the UK.

42 f vehicle or 10 ug ethinyl estradiol + 20 ug levonorgestrel (HCs) throughout adolescence from postnat

43 tic analog found in hormonal contraceptives, levonorgestrel, impacts sequential influenza A virus inf

44 depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel implant (LNG), and a copper intrauterine

45 depot medroxyprogesterone acetate (DMPA-IM), levonorgestrel implant (LNG-implant), or copper intraute

46 Levonorgestrel implants were inserted at baseline in all

47 through their influence on the solubility of levonorgestrel in the silicone elastomer.

48 contraceptive (IUC) continuation between the levonorgestrel intrauterine system (LNG-IUS) and copper

49 We aimed to assess whether a levonorgestrel intrauterine system could modulate the ut

50 rveillance before and after insertion of the levonorgestrel intrauterine system for 12 months.

51 el), 1.6 (95% CI, 1.55-1.69); and users of a levonorgestrel intrauterine system, 1.4 (95% CI, 1.31-1.

52 men who require long-term anticoagulation, a levonorgestrel intrauterine system, tranexamic acid (dur

53 ase behavior make formulation development of levonorgestrel intrauterine systems (LNG-IUSs) formidabl

54 en high contraceptive efficacy and safety of levonorgestrel intrauterine systems (LNG-IUSs), no gener

55 ause data are lacking on the efficacy of the levonorgestrel IUD for this purpose.

56 ment occurred in 5.2% of participants in the levonorgestrel IUD group and 4.9% of those in the copper

57 ), consistent with the noninferiority of the levonorgestrel IUD to the copper IUD.

58 The levonorgestrel IUD was noninferior to the copper IUD for

59 55 participants randomly assigned to receive levonorgestrel IUDs and 356 assigned to receive copper I

60 more intrauterine device (IUD) users select levonorgestrel IUDs than copper IUDs for long-term contr

61 proved from baseline to 6 months in both the levonorgestrel-IUS group and the usual-treatment group (

62 al health) were significantly greater in the levonorgestrel-IUS group than in the usual-treatment gro

63 period but were significantly greater in the levonorgestrel-IUS group than in the usual-treatment gro

64 571 women with menorrhagia to treatment with levonorgestrel-IUS or usual medical treatment (tranexami

65 ears, more of the women were still using the levonorgestrel-IUS than were undergoing the usual medica

66 who presented to primary care providers, the levonorgestrel-IUS was more effective than usual medical

67 evonorgestrel-releasing intrauterine system (levonorgestrel-IUS) with usual medical treatment in wome

68 ucted a pilot study with 30 women initiating levonorgestrel (LNG) containing combined oral contracept

69 erone acetate (DMPA-IM), copper-IUD, and the levonorgestrel (LNG) implant on cervical T cells.

70 M, a copper intrauterine device (IUD), and a levonorgestrel (LNG) implant-on human immunodeficiency v

71 patches containing the contraceptive hormone levonorgestrel (LNG) into an earring, a ring, a necklace

72 ne (PDMS) based long-acting (e.g. 3-5 years) levonorgestrel (LNG) intrauterine systems (IUSs), such a

73 (TFV) intravaginal rings (IVRs) with/without levonorgestrel (LNG) on the genital microbiota of Kenyan

74 t is filled with a formulation of progestin [levonorgestrel (LNG) or etonogestrel (ENG)], or a formul

75 rone acetate (MPA), norethindrone (NET), and levonorgestrel (LNG)) used by women as contraceptives in

76 with placebo or one of two progestins, P4 or levonorgestrel (LNG), and infected with a mouse-adapted

77 Some progestins, such as levonorgestrel (LNG), exert androgenic effects in mammal

78 to delay release of a contraceptive hormone, levonorgestrel (LNG), for 6 months.

79 The growing popularity of levonorgestrel (LNG)-releasing intra-uterine systems for

80 200 ng/L P4, RU486, norethindrone (NET), and levonorgestrel (LNG).

81 carrageenan (CG; targets HPV and HSV-2), and levonorgestrel (LNG; targets unintended pregnancy).

82 (Pritelivir, PTV) and a contraceptive drug (Levonorgestrel, LNG) were loaded in a macaque size IVR (

83 ature, levonorgestrel particle size, initial levonorgestrel loading and silicone elastomer type were

84 30 mg ulipristal acetate (n=1104) or 1.5 mg levonorgestrel (n=1117) orally.

85 xual intercourse (ulipristal acetate, n=844; levonorgestrel, n=852).

86 , Medroxyprogesterone acetate (MPA), but not Levonorgestrel, Norethisterone or progesterone, suppress

87 The greatest concern is associated with levonorgestrel, norethisterone, and gestodene and their

88 The levonorgestrel-only regimen (levonorgestrel, 0.75 mg, re

89 a single concentration of 100 ng/L of either Levonorgestrel or Gestodene stopped spawning almost comp

90 Cure time, cure temperature, levonorgestrel particle size, initial levonorgestrel loa

91 retroviral therapy (ART) coadministration on levonorgestrel pharmacokinetics.

92 argest randomized, controlled trial to date, levonorgestrel prevented about 85% of pregnancies that w

93 stogen (depot medroxyprogesterone acetate or levonorgestrel releasing intrauterine system) or the com

94 Most IUDs were levonorgestrel-releasing (259 234 [79.4%]).

95 roxyprogesterone acetate (DMPA; n = 32), the levonorgestrel-releasing intrauterine device (LNG-IUD; n

96 cases, myocardial infarction except for the levonorgestrel-releasing intrauterine device, which was

97 lticenter, randomized trial, we compared the levonorgestrel-releasing intrauterine system (levonorges

98 The levonorgestrel-releasing intrauterine system (LNG-IUD),

99 l and cervical biopsies from women using the levonorgestrel-releasing intrauterine system (LNG-IUS, n

100 The association between the use of a levonorgestrel-releasing intrauterine system and reducti

101 The levonorgestrel-releasing intrauterine system had a prote

102 The levonorgestrel-releasing intrauterine system is consider

103 t-time users of low-, medium-, and high-dose levonorgestrel-releasing intrauterine systems (LNG-IUSs)

104 increased risk of incident HIV diagnosis for levonorgestrel-releasing IUDs versus copper IUDs.

105 repurposing analyses (such as pioglitazone, levonorgestrel, salsolidine, ginkgolide A, and icariin).

106 Levonorgestrel subdermal implants are preferred contrace

107 F1 generations, and for ethinylestradiol and levonorgestrel, the F2 also.

108 , the ability of the contraceptive progestin levonorgestrel to bind chemically with hydrosilane group